Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

NCT05468359 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Refractory Solid Tumor
Hepatocellular Carcinoma
Malignant Solid Tumor
Pediatric Cancer
Pediatric Solid Tumor
Fibrolamellar Carcinoma

Interventions

DRUG: Atezolizumab
DRUG: Sorafenib
DRUG: Bevacizumab
DRUG: Cyclophosphamide

Sponsor

St. Jude Children's Research Hospital